Naurex Raises $80m in Series C Financing Round

Naurex Inc., a biopharmaceutical company leveraging its uniqueplatform to develop novel drugs for diseases of the central nervous system (CNS), today announced thecompletion of an $80 million Series C financing round. New investors participating in the round include Cowen Investments, EcoR1 Capital, Goudy Park Capital,Portola Capital Partners and Sabby Capital. Existing investors also participated in…


Takeda gets a ‘breakthrough’ tag for PhIII rare disease drug

With its bottom line getting squeezed and big budget cuts looming, Takeda and its new president, Christophe Weber, issued some upbeat news today for a change. The FDA has branded its top late-stage drug prospect ixazomib (MLN9708)–a multiple myeloma treatment designed to succeed the top-selling blockbuster Velcade–as a “breakthrough” therapy deserving VIP status with regulators.


Is Amgen The Next Big Split?

First Abbott split and created AbbVie, then Baxter with Baxalta, is Amgen up next? I am placing best the new spin off will be called Pmgen. Hedge fund manager Daniel Loeb is lending his voice to the chorus of investors who believe Amgen ($AMGN) would do better as two companies. And his firm, Third Point,…


FDA Extends Exclusivity for Certain Combo-Meds

What’s two extra years of exclusivity worth? Enough to spark a legal fight. The FDA posted new guidance on its website Friday, awarding certain combo meds 5 years of exclusivity compared with the previous three. Drugmakers had lobbied for the change, but the timing–and the wording–are bound to be controversial.

man woman hands holding broken heart

Are Shire and AbbVie on the Outs?

Following Shire plc’s (“Shire”) waiver of the three-day notice period, AbbVie Inc. (“AbbVie”) (NYSE: ABBV) announces today its Board of Directors’ withdraws its recommendation made on July 18, 2014 regarding the proposed Shire transaction and recommends that stockholders vote against the transaction.

Copyright © 2014 WhiteCityNews, All rights reserved.